Abstract
Type 2 diabetes is characterized by insulin resistance together with progressive loss of beta-cell function. After recognition of gluco- and lipo-toxicity, attention was focused on the preservation and/or restoration of beta cell function, especially at the early stages of the diabetes, with better beta-cell reserve and in the absence of complications. Early treatment of glucotoxicity with insulin was searched by early insulin treatment studies, and these studies have some promising results, pointing the possibility of “remission” of diabetes in some patients. According to the results of these studies, patients with early diagnosis of diabetes, the ones with better beta cell reserve, patients with low tendency for “insulin-abuse” could make “U”-turn from insulin to pills or even drug-free life. Criteria to turn back to pills could be listed as disappearance of diabetic symptoms, daily insulin need < 0.25 unit/kg, euglycemia in both fasting and postprandial state, and better beta cell function. The main problems in early insulin treatment are the ‘’insulin resistance’’ of both patients and doctors, hypoglycemia, weight gain and increased appetite. Meanwhile, hyperinsulinemia desensitizes receptors and causes worsening of situation in a vicious cycle of insulin resistance and hyperglycemia. Therefore, patients should be selected properly and U-turn could be performed in relevant conditions explained in the text. It could be possible to see early insulin treatment and U-turn strategies in future guidelines for type 2 diabetes.
Keywords: Amylin, beta cell, glucotoxicity, insulin, oral antidiabetics, type 2 diabetes.
Current Vascular Pharmacology
Title:Is there U-turn from Insulin Back to Pills in Diabetes?
Volume: 12 Issue: 4
Author(s): Sibel Ertek and Sevki Cetinkalp
Affiliation:
Keywords: Amylin, beta cell, glucotoxicity, insulin, oral antidiabetics, type 2 diabetes.
Abstract: Type 2 diabetes is characterized by insulin resistance together with progressive loss of beta-cell function. After recognition of gluco- and lipo-toxicity, attention was focused on the preservation and/or restoration of beta cell function, especially at the early stages of the diabetes, with better beta-cell reserve and in the absence of complications. Early treatment of glucotoxicity with insulin was searched by early insulin treatment studies, and these studies have some promising results, pointing the possibility of “remission” of diabetes in some patients. According to the results of these studies, patients with early diagnosis of diabetes, the ones with better beta cell reserve, patients with low tendency for “insulin-abuse” could make “U”-turn from insulin to pills or even drug-free life. Criteria to turn back to pills could be listed as disappearance of diabetic symptoms, daily insulin need < 0.25 unit/kg, euglycemia in both fasting and postprandial state, and better beta cell function. The main problems in early insulin treatment are the ‘’insulin resistance’’ of both patients and doctors, hypoglycemia, weight gain and increased appetite. Meanwhile, hyperinsulinemia desensitizes receptors and causes worsening of situation in a vicious cycle of insulin resistance and hyperglycemia. Therefore, patients should be selected properly and U-turn could be performed in relevant conditions explained in the text. It could be possible to see early insulin treatment and U-turn strategies in future guidelines for type 2 diabetes.
Export Options
About this article
Cite this article as:
Ertek Sibel and Cetinkalp Sevki, Is there U-turn from Insulin Back to Pills in Diabetes?, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/15701611113119990122
DOI https://dx.doi.org/10.2174/15701611113119990122 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Insect Peptides – Perspectives in Human Diseases Treatment
Current Medicinal Chemistry Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Roles of SM22α in Cellular Plasticity and Vascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Gadd45 Proteins as Critical Signal Transducers Linking NF-κB to MAPK Cascades
Current Cancer Drug Targets Subject Index to Volume 3
Current Gene Therapy The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Anti-Cancer Agents in Medicinal Chemistry Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Role of Mechanoinsensitive Nociceptors in Painful Diabetic Peripheral Neuropathy
Current Diabetes Reviews Renal and Hepatic Kinetics of Tc-99m-labelled Hexakis-methoxy-isobutyl Isonitrile
Drug Metabolism Letters Proteomics Using Mammospheres as a Model System to Identify Proteins Deregulated in Breast Cancer Stem Cells
Current Molecular Medicine